Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept ...

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a strong buy.

This South San Francisco company would be the first Bay Area biotech company to go public this year, proving that the SPAC ...

Understanding your tumor biology is key to finding the right treatment for pancreatic cancer. Identifying mutations, or changes in a [...] READ MORE ...

RAS G12D is one of the most frequent mutations in RAS, and when it occurs, it leaves RAS in a permanently active state, causing the cell to proliferate uncontrollably. Examples of the so-called ...

A breakthrough in lung cancer treatment may be on the horizon. Scientists at VCU Massey Comprehensive Cancer Center have ...

GLP-1RAs were not associated with an increased risk for thyroid cancer relative to DPP-4 inhibitor use among an international cohort.

A second drug candidate, BBO-10203, blocks the interaction between RAS and PI3K alpha ... evaluating BBO-10203 in advanced cases of breast cancer, colorectal cancer, and non-small cell lung ...

Patients with T2D who undergo kidney transplants are less likely to experience organ failure and mortality if they receive ...

In 2024 we built on our record of execution by advancing our highly differentiated portfolio of RAS-focused investigational drugs, making ...